Clinical readout

Evaxion's EVX-01 cancer vaccine shows broad T-cell responses in phase 2 melanoma data

New biomarker results from the phase 2 study of the personalized vaccine EVX-01 in advanced melanoma found that most chosen vaccine targets triggered tumour-specific immunity, and CD8 responses appeared in half of patients. After two years, 12 of 16 patients had responded, four of them completely. Patients began treatment with EVX-01 plus Keytruda.

Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call